Jefferies Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
Jefferies has initiated coverage on Oruka Therapeutics with a Buy rating and set a price target of $40.
September 13, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has initiated coverage on Oruka Therapeutics with a Buy rating and a price target of $40, indicating a positive outlook for the stock.
The initiation of coverage by Jefferies with a Buy rating and a $40 price target suggests a positive sentiment towards Oruka Therapeutics. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100